Neuroethics Working Group (NEWG) Workshop on Continuing Trial Responsibilities
Part 1 Virtual Agenda - Tuesday, May 24, 2022
Zoom Session (Times are ET) - Open to the Public

12:00 PM    Welcome
John Ngai, PhD – Director, NIH BRAIN Initiative

12:05 PM    Introduction and background
Saskia Hendriks, MD, PhD – Clinical Center, NIH

12:15 PM    Panel 1: What needs may study participants have in relation to their trial participation, after a trial ends?
• Brandy Ellis
  o Patient-Participant
• Jen French
  o Executive Director, Neurotech Network
• Gabriel Lázaro-Muñoz, PhD, JD
  o Assistant Professor, Center for Bioethics at Harvard Medical School
• James Mahoney, PhD
  o Assistant Professor/Clinical Neuropsychologist, West Virginia Univ

1:15 PM    Panel 1 Discussion: Co-Moderators: Winston Chiong, MD, PhD + Nina Hsu, PhD

1:45 PM    BREAK

2:30 PM    Panel 2: What do different stakeholders currently provide, and what can/could they provide in terms of research-related care needs?
• Yagna Pathak, PhD
  o Staff Research Scientist, Abbott Neuromodulation
• Martha Morrell, MD
  o Stanford University
• Carl Li, MD
  o Medical Officer, Centers for Medicare & Medicaid Services (CMS)
• Rhonda Robinson Beale, MD
  o SVP Deputy Chief Medical Officer, United Health Group
• Shirley McCartney, PhD
  o Director, Clinical Research Neurological Surgery, OHSU
• Nick Langhals, PhD
  o Program Director, Division of Translational Research, NINDS

4:00 PM    Panel 2 Discussion: Co-Moderators: Sameer Sheth, MD, PhD + Nina Hsu, PhD

4:45 PM    Day 1 wrap up

5:00 PM    Adjourn
Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Neuroethics Working Group (NEWG) Workshop on Continuing Trial Responsibilities
Part 2 Virtual Agenda - Wednesday, May 25, 2022
Zoom Session (Times are ET) - Open to the Public

12:00 PM  Welcome
John Ngai, PhD – Director, NIH BRAIN Initiative

12:05 PM  Recap of Day 1
Nina Hsu, PhD

12:30 PM  Panel 3: What should be the minimum in research-related care that should be facilitated in implanted neural device trials? When would stakeholders have responsibilities to provide or facilitate more than the previously defined minimum?
- Tracy Dixon-Salazar, PhD
  - Executive Director, LGS Foundation
- Patricio Riva Posse, MD
  - Assistant Professor, Emory University
- Sara Goering, PhD
  - Professor of Philosophy and the Program on Ethics, U Washington
- Ishan Dasgupta, JD, MPH
  - Fellow, Neuroscience & Society, Dana Foundation
- Luann E. Van Campen, PhD, MA
  - Founder and President, Ethics Matters LLC
- John Marler, MD
  - Acting Clinical Deputy Director, Division of Neurological and Physical Medicine Devices, Center for Devices and Radiological Health, US Food and Drug Administration

1:45 PM  Panel 3 Discussion: Co-Moderators: Christine Grady, MSN, PhD, + Saskia Hendriks, MD, PhD

2:30 PM  BREAK

3:00 PM  Forum with all stakeholders
  i. What are the gaps between what is currently facilitated and what is sufficient/appropriate? How can we best fill those gaps?
  Co-moderators: Hank Greely, JD, and Saskia Hendriks, MD, PhD

4:30 PM  Day 2 wrap up

4:45 PM  Adjourn